Turnstone Biologics to Present at the 2024 Bank of America Securities Health Care Conference
Turnstone Biologics to Present at the 2024 Bank of America Securities Health Care Conference
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced that Sammy Farah, M.B.A., Ph.D., President and Chief Executive Officer, will present at the upcoming Bank of America Securities Health Care Conference on Wednesday, May 15, 2024, in Las Vegas, Nevada. The presentation will begin at 11:35 a.m. P.T. / 2:35 p.m. E.T.
圣地亚哥，2024年5月8日（GLOBE NEWSWIRE）——Turnstone Biologics Corp.（“Turnstone” 或 “公司”）（纳斯达克股票代码：TSBX）是一家临床阶段的生物技术公司，通过开创精选的肿瘤浸润淋巴细胞（精选TIL）疗法，开发差异化方法来治疗和治愈实体瘤患者，今天宣布，工商管理硕士，博士萨米·法拉总裁兼首席执行官将出席即将于2024年5月15日星期三在内华达州拉斯维加斯举行的美国银行证券医疗保健会议。演讲将于太平洋时间上午 11:35 /美国东部时间下午 2:35 开始
To access a live webcast of the presentation, please visit the Events page in the Investors section of the Company's website at . A webcast replay will be available for a limited period.
要观看演讲的网络直播，请访问公司网站 “投资者” 部分的 “活动” 页面，网址为。网络直播重播将在有限的时间内提供。
Members of Turnstone's senior management will also be available for one-on-one meetings during the conference. Interested investors should contact their Bank of America Securities representative for further information.
会议期间，Turnstone的高级管理层成员也将参加一对一的会议。感兴趣的投资者应联系其美国银行证券代表以获取更多信息。
About Turnstone
关于 Turnstone
Turnstone Biologics is a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy. Turnstone's next-generation TIL therapy is based upon the identification, selection and expansion of the most potent tumor-reactive T cells, known as Selected TILs, and is designed to overcome the limitations of first-generation bulk TIL that have demonstrated objective responses only in limited tumor types. Turnstone's most advanced program, TIDAL-01, is currently being evaluated in multiple Phase 1 studies in patients with colorectal cancer, breast cancer, head and neck cancer, uveal melanoma, and cutaneous melanoma. The Company is also actively advancing its preclinical pipeline programs including TIDAL-02, its next Selected TIL program, and its TIDAL-01 and viral immunotherapy combination program. For additional information about Turnstone, please visit , and follow us on LinkedIn.
Turnstone Biologics是一家临床阶段的生物技术公司，通过开创精选的肿瘤浸润淋巴细胞（精选TIL）疗法，开发了一种差异化的治疗和治愈实体瘤患者的方法。Turnstone的下一代TIL疗法基于对最有效的肿瘤反应性T细胞（即精选TIL）的鉴定、选择和扩展，旨在克服第一代散装TIL的局限性，这种局限性仅在有限的肿瘤类型中表现出客观的反应。Turnstone最先进的项目 TIDAL-01 目前正在对结直肠癌、乳腺癌、头颈癌、葡萄膜黑色素瘤和皮肤黑色素瘤患者的多项1期研究进行评估。该公司还积极推进其临床前研发项目，包括 TIDAL-02、其下一个精选 TIL 项目以及 TIDAL-01 和病毒免疫疗法组合计划。有关Turnstone的更多信息，请访问并在LinkedIn上关注我们。
Contact
联系我们
Ahmed Aneizi
Investor Relations
Turnstone Biologics
(347) 897-5988
ahmed.aneizi@turnstonebio.com
艾哈迈德·阿内齐
投资者关系
Turnstone 生物制剂
(347) 897-5988
ahmed.aneizi@turnstonebio.com
译文内容由第三方软件翻译。